Exocrine Pancreatic Insufficiency Drug Development- Pipeline Analysis Report

Exocrine Pancreatic Insufficiency Drug Development- Pipeline Analysis Report

  • May 2018 •
  • Report ID: 5390312 •
  • Format: PDF
Absence of adequate digestive enzymes in a patient results in occurrence of Exocrine Pancreatic Insufficiency (EPI). Pancreas fail to produce the required enzymes to digest food and nutrient absorption. The market is valued at around $1.2 billion.

Over 10 companies and universities are focusing on developing treatment options for Exocrine Pancreatic Insufficiency.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Exocrine Pancreatic Insufficiency pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Exocrine Pancreatic Insufficiency pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Exocrine Pancreatic Insufficiency pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.